slides · global inventory
Analyze Data
Slide function collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 58,039
Current window 38,731-38,760
Pages 1,935
Rows per page 30
Slide function
38,731-38,760 of 58,039
81
The slide uses a dot plot to show binding affinity vs sequence diversity and a bar chart to compare binding rates.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
82
The slide shows two dose-response curves (Cell Surface Binding and ADCC) and two molecular surface models for epitope mapping.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
88
The slide uses a process flow (1 -> 2) followed by a scatter plot validation and a summary table of Pearson R values.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
89
SPR stands for Surface Plasmon Resonance. The charts show binding affinity (KD) comparisons.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
98
The scatter plot shows a Pearson R of 0.74 for N=5389 data points.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
102
Includes a Kaplan-Meier survival curve and a biological diagram of TLS.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
14
The slide uses a comparative bar chart approach to justify the human half-life prediction based on NHP data.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
16
The slide uses a combination of a pharmacokinetic simulation line chart and a bar chart showing clinical remission rates by exposure quartile.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
37
Includes a footnote regarding a 1-for-25 reverse stock split effective September 8, 2023.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
14
Includes PK modeling data comparing human and NHP half-lives and steady-state concentration simulations.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
16
The slide uses a bar chart to show dose-response correlation and a line chart to show pharmacokinetic modeling.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
38
Includes a footnote regarding a 1-for-25 reverse stock split effective September 8, 2023.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
14
The chart displays longitudinal data for three cell types over 35 days, highlighting the differential pharmacodynamic response.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
17
The slide presents clinical trial safety data (ARTISTRY-1) comparing monotherapy and combination therapy cohorts.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
18
The slide uses a human body diagram to map clinical responses (CR, PR, uPR) by tumor type and treatment regimen.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
19
Includes a swimmer plot (onco-plot) and a summary table of best overall response (BOR) metrics.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
21
Includes a swimmer plot (left) and a summary table (right) with clinical trial metrics.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Loop · Before After1 hit
30
Data shows that while WT IL-18 is inhibited by IL-18BP, the variants are resistant to this inhibition.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
35
Includes a footnote regarding patient enrollment for clinical milestones.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Financials1 hit
04
The slide highlights significant growth in revenue and net income metrics year-over-year.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Problem1 hit
05
Includes a blue box highlight around the Q3'23 column.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations 1 hit
06
Includes both GAAP and non-GAAP projections, plus specific product revenue breakdowns.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations 1 hit
08
The chart illustrates the revenue contribution of four specific products (VIVITROL, ARISTADA, VUMERITY, LYBALVI) over time.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Solution1 hit
09
Includes a disclaimer regarding the forward-looking nature of the expectations.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Solution1 hit
10
The chart tracks TRx (Total Prescriptions) over 101 weeks.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Solution1 hit
11
Alkermes | Results Presentation Deck | 27 slidesAlkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Solution1 hit
12
Alkermes | Results Presentation Deck | 27 slidesAlkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Solution1 hit
17
Includes box plots for AUC and Cmax across dose levels (1, 3, 8, 15, 25, 50 mg).Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Market Size1 hit
19
The slide presents clinical trial baseline data for a very small sample size (N=4).Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Market Size1 hit
20
The table displays n (%) for adverse events related to the study drug.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Market Size1 hit